NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

Second Quarter 2010 Targets in Oncology Updates and Additions

  • Anaplastic lymphoma kinase (ALK)
  • B-cell CLL/lymphoma 6 (BCL6)
  • Bromo adjacent homology domain-containing protein 1 (BAHD1)
  • CD38
  • Cyclin-dependent kinase (Cdk) family
  • Echinoderm microtubule associated protein like 4 (EML4)
  • Excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1)
  • Gonadotropin-releasing hormone receptor (GnRHr)
  • Hedgehog (Hh) signaling pathway
  • Insulin-like growth factor (IGF)
  • Insulin receptor substrate 1 (IrS1)
  • Interferon regulatory factor 3 (IRF3) KDM1A
  • Mammalian target of rapamycin (mTOR)
  • Neuropilin 1 (NRP1, NRP-1)
  • Neuropilin (NRP)
  • Polycomb group ring finger 4 (PCGF4)
  • Ret proto-oncogene (RET)
  • Serine/threonine kinase 33 (STK33)

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM